Investigative Ophthalmology & Visual Science Cover Image for Volume 61, Issue 7
June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Agreement between 10-2 and 24-2C visual field tests for detecting glaucomatous central visual field defects
Author Affiliations & Notes
  • Tutul Chakravarti
    Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
    Ophthalmology, Glaucoma, EYE & GLAUCOMA CARE AND VIMS, Kolkata, West Bengal, India
  • Mohamad Moghadam
    Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Christopher Bowd
    Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • James Alexander Proudfoot
    Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Robert Weinreb
    Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Linda M Zangwill
    Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Footnotes
    Commercial Relationships   Tutul Chakravarti, None; Mohamad Moghadam, None; Christopher Bowd, None; James Proudfoot, None; Robert Weinreb, Aerie , Allergan, Bausch&Lomb,Eyenovia (C), Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Optovue, Centervue, Bausch&Lomb (F), Toromedes, Meditec-Zeiss (P); Linda Zangwill, Heidelberg Engineering, (R), Meditec-Zeiss (P), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc. (F)
  • Footnotes
    Support  Fulbright -Nehru Academic and Professional Excellence Fellowship (Award No 2513/F-NAPE/2019), P30EY022589), EY11008
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4048. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tutul Chakravarti, Mohamad Moghadam, Christopher Bowd, James Alexander Proudfoot, Robert Weinreb, Linda M Zangwill; Agreement between 10-2 and 24-2C visual field tests for detecting glaucomatous central visual field defects. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4048.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the agreement between Humphrey Visual Field Analyzer 10-2 and 24-2C test patterns for detecting defects in the central 10 degrees of the visual field (central visual field defects, CVFDs).

Methods : In this cross-sectional study, one hundred and eight healthy, glaucoma suspect and glaucoma patients from the ongoing Diagnostic Innovations in Glaucoma Study (DIGS), who completed 10-2 and 24-2C VF testing within six months were included. 10-2 and 24-2C CVFDs were categorized into patterns of defect (including arcuate, partial arcuate, altitudinal, and widespread) by two independent graders based on total deviation (TD) and pattern deviation (PD) plots, with a consensus grade reached when there was disagreement. Cohen’s Kappa (k) statistic was used to assess agreement between 10-2 and 24-2C tests in identifying CVFDs, with bias-corrected confidence intervals determined by a clustered bootstrap procedure.

Results : The mean age of the population was 68.8 years and mean (95% CI) 10-2 mean deviation of study participants was -2.86 dB (-3.70 to -2.03). A CVFD was identified in 51 (28%) and 44 (25%) of 10-2 tests on TD and PD plots, respectively, and on 36 (20%) of 24-2C measurements (by both TD and PD criteria). Assessment of 10-2 and 24-2C tests results showed substantial agreement when identifying any CVFD with both TD (k = 0.67 [0.54-0.80]) and PD (k = 0.68 [0.54-0.79]) outside of normal limits. Similar levels of agreement were observed when identifying any superior (TD k = 0.67 [0.51-0.81], PD k = 0.62 [0.41-0.76]) or inferior CVFDs (TD k = 0.63 [0.49-0.78], PD k = 0.59 [0.40- 0.75]). Decreased agreement was observed when identifying specific patterns of CVFD.

Conclusions : The recently available 24-2C HFA 3 test pattern shows substantial agreement in assessing CVFD with 10-2 test pattern CVFD and may be considered as an alternative to 10-2 VF test for detecting central visual field defects.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×